A five-point plan against pandemics
Op-ed by Stefan Oschmann, CEO of Merck KGaA, Darmstadt, Germany, and Wolfgang Ischinger, Chairman of the Munich Security Conference, in "EURACTIV" and “Handelsblatt“ from March 30, 2020
Read the full article
“We need to look at every single tool we have”
We are supporting more than 50 Covid-19 vaccine projects worldwide. Ranjeet Patil, Segment Head Cell and Gene Therapy explains how we are helping scientists and which hurdles must be overcome.
Read the full interviewMerck/EFPIA video. We Won’t Rest to serving patients, scientists and healthcare providers
At Merck we are supporting from many ways the global fight against Covid-19. From protection, prevention and treatment, colleagues from healthcare, life science and performance materials are a key part of our joint efforts against pandemic.
Committed to fight Covid-19
290k
units of interferon beta-1a (Rebif®) donated to the World Health Organization
150k
liters of disinfectants made available to the state of Hesse
Related News
All stories at a glance-
Press Releases
Merck KGaA, Darmstadt, Germany statement on Rebif® (interferon beta-1a) contribution ...
As part of the global effort to investigate potential COVID-19 therapeutics and our support of independent research, Merck KGaA, Darmstadt, Germany is collaborating with the US National Institute of Allergy ...
2020/08/05
-
Press Releases
New Report Identifies Paths to Pandemic Resilience
A new report details potential paths to solutions to overcoming the global Covid-19 crisis and ways to prepare for or even prevent a future pandemic.
2020/07/01
-
Press Releases
Merck KGaA, Darmstadt, Germany, Initiates First Clinical Trial of TLR7 and ...
Merck KGaA, Darmstadt, Germany today announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application for M5049 for the treatment of patients with Covid-19 pneumonia.
2020/06/25
Cooperation with IAVI and Serum Institute of India
Together with nonprofit scientific research organization IAVI and biologics manufacturer Serum Institute of India we aim to develop monoclonal antibodies to address Covid-19.
A Phase I clinical trial is expected to start early in 2021. The SARS-CoV-2 neutralizing antibodies were co-invented by IAVI and Scripps Research.
More information is available here.
We collaborate with the Bill & Melinda Gates Foundation to fight COVID-19
On March 26, a consortium of healthcare and life sciences companies together with the Bill & Melinda Gates Foundation announced an important collaboration to accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for Covid-19. We are proud to be part of this group. All partners contribute a range of assets, resources, and expertise needed to identify effective and scalable solutions to the pandemic, which is affecting billions worldwide.
More information is available here.
On September 30 we reinforced our collaboration by signing an agreement to help accelerate the end of the pandemic. This communique reflects the joint commitment on behalf of 15 life science and healthcare companies and the Bill Melinda Gates Foundation to enhance access for everyone around the world to Covid-19 vaccines, therapeutics, and diagnostics, regardless of their income.
More information is available here.
Human progress is what we stand for. During these difficult times, we actively contribute resources, full dedication and expertise to fight this COVID-19 pandemic.
A Message from the Executive Board
"All of us at Merck KGaA, Darmstadt, Germany, 57,000 people in 66 countries, are dedicated to serving patients, scientists and customers around the globe."
Read more
Future Insight Prize: Fighting the pandemic
With our support, Pardis Sabeti and James Crowe are working on new diagnostics and treatment options for Covid-19.
Read morePanel Discussion: Fighting the Pandemic
Stefan Oschmann, Pardis Sabeti, James Crowe and Subhanu Saxena came together virtually to exchange thoughts regarding the Covid-19 situation and share their vision for the future.
Watch full recording
Expediting Your Covid-19 Response & Vaccine Research
As a global life science tools and equipment supplier, we are here to help in the response to Covid-19. From supplying raw materials and research products for detection and characterization to production, we’ve consolidated relevant product and service offerings within a single page.
Read more
Research Grant for Pandemic Preparedness
The threat from newly emerging viral infections is a global challenge for humanity. We offer research grants for technological solutions towards pandemic preparedness or solutions that could help fighting emerging viral infections.
Read more
How Merck KGaA, Darmstadt, Germany became a manufacturer of disinfectant
Two sites recently demonstrated how the Covid-19 crisis could unlock unimaginable potential and how combining existing competencies and resources made this happen.
Read more
Face shields from a 3D printer
How the Innovation Center team is helping relieve the shortage of personal protective equipment.
Read more
Global Health in times of Covid-19
According to the World Health Organization, at least half of the world’s population does not have access to essential health care. In times of Covid-19, the most vulnerable countries will be worst affected.
Read more